Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.

ABSTRACT:

Importance

Recently, genetic polymorphism in HSD3B1 encoding 3β-hydroxysteroid dehydrogenase-1 has been shown to be associated with oncological outcome when treated with androgen-deprivation therapy (ADT) for prostate cancer. Upfront abiraterone combined with ADT has proved survival benefit. However, its effect on oncological outcome among different ethnicities and in abiraterone treatment remain unclear.

Objective

To investigate the significance of missense polymorphism in HSD3B1 gene among men treated with primary ADT or abiraterone.

Design, setting, and participants

This prognostic study included Japanese patients with metastatic hormone-sensitive prostate cancer between June 1993 and July 2005 and with castration-resistant prostate cancer between September 2014 an

SUBMITTER: Shiota M 

PROVIDER: S-EPMC6484618 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature